Cancer Cell
Volume 27, Issue 1, 12 January 2015, Pages 123-137
Journal home page for Cancer Cell

Article
Dual-Action Combination Therapy Enhances Angiogenesis while Reducing Tumor Growth and Spread

https://doi.org/10.1016/j.ccell.2014.10.015Get rights and content
Under an Elsevier user license
open archive

Highlights

  • Vascular promotion is distinct from antiangiogenesis and vascular normalization

  • Vascular promotion enhances tumor angiogenesis, flow, leakiness, and drug delivery

  • Vascular promotion reduces tumor growth and metastasis while extending survival

  • Low-dose Cilengitide enhances Gemcitabine uptake and metabolism within tumor cells

Summary

Increasing chemotherapy delivery to tumors, while enhancing drug uptake and reducing side effects, is a primary goal of cancer research. In mouse and human cancer models in vivo, we show that coadministration of low-dose Cilengitide and Verapamil increases tumor angiogenesis, leakiness, blood flow, and Gemcitabine delivery. This approach reduces tumor growth, metastasis, and minimizes side effects while extending survival. At a molecular level, this strategy alters Gemcitabine transporter and metabolizing enzyme expression levels, enhancing the potency of Gemcitabine within tumor cells in vivo and in vitro. Thus, the dual action of low-dose Cilengitide, in vessels and tumor cells, improves chemotherapy efficacy. Overall, our data demonstrate that vascular promotion therapy is a means to improve cancer treatment.

Cited by (0)